Objective: explore the association between percutaneous nephrostomy and survival of patients with advanced cervical cancer accompanied by renal impairment.Materials and Methods: Retrospective cohort, with 70 samples taken with consecutive sampling. The population was all advanced cervical cancer patients with impaired renal function (IIIB, IVA, IVB, recurrent) treated in RSUPNCM since January 1, 1998. Sample size was each 19 patients for percutaneous nephrostomy and conservative groups. Survival was measured from medical records of advanced cervical cancer patients with impaired renal function who were treated at RSUPNCM since January 1, 1998 until December 31, 2003. Percutaneous nephrostomy was measured from medical records of advanced cervical cancer patients with impaired renal function treated at RSUPNCM since 1 January 1998 until December 31, 2003.Results: Median survival of 44 respondents who underwent percutaneous nephrostomy was 203 days with probability of survival at 6 months 56.9% and 12 months by 31.1%. Median survival of 26 respondents who did not undergo percutaneous nephrostomy was 75 days with a chance of survival at 6 months 26.6% and 12 months 10%. There were significant differences between patients undergoing percutaneous nephrostomy and those without (p = 0.0470, α = 0.05).Conclusion: There was significant association between percutaneous nephrostomy and survival (p = 0.0470, α = 0.05).
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
